About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials | 6,587 Studies Recruiting

Clinical TrialsLymphoma

Lymphoma Clinical Trials

Browse 6,587 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 3601-3620 of 6,587 trials

Active not recruitingA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular LymphomaThis study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular…NCT04246086·Duarte, California and 25 others

Related Searches

hodgkintrials non-hodgkintrials

Data from ClinicalTrials.govTerms

CompletedOblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.NCT00070083·Stanford, California and 3 others

CompletedStudying Genes Associated With Non-Hodgkin Lymphoma in Young PatientsThis research studies genes associated with non-Hodgkin lymphoma in young patients.NCT01623856·Monrovia, California

RecruitingEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use DisorderThe primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in…NCT06651177·Jacksonville, Florida and 8 others

Not yet recruitingTesting the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaThis phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high grade (double hit) B- cell lymphomas that are newly…NCT07724457

CompletedAn Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaThe purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.NCT01592370·Clovis, California and 42 others

CompletedPharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular LymphomaThe primary objective of the study is to assess the pharmacokinetic (PK) similarity of Boehringer Ingelheim (BI) 695500 vs. rituximab (MabThera®) in previously untreated patients…NCT01950273·Canberra, Migration Data and 28 others

UnknownA Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).NCT04398953·Hefei, Anhui and 38 others

UnknownInvolved Field Radiotherapy for Non-gastric Marginal Zone LymphomaThis prospective study will test the following hypotheses in patients with stage I-II low grade marginal zone (MZ) lymphoma: * Involved Field Radiotherapy will produce a complete…NCT00377195·Camperdown, New South Wales and 4 others

TerminatedA Phase I Study of CD19 Specific T Cells in CD19 Positive MalignancyIn particular circumstances T cells can be an effective treatment for malignant disease, for example, donor lymphocyte infusions following allogeneic transplants or treatment of…NCT01493453·Manchester

WithdrawnPhenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive CancerRATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus.NCT00387530·La Jolla, California

TerminatedBrentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)The goal of this clinical research study is to study the safety of ADCETRISTM (brentuximab vedotin) in patients with Hodgkin lymphoma or ALCL who have had an allogeneic or…NCT02169505·Houston, Texas

TerminatedStudy of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin LymphomasThis is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin…NCT05965505·Beijing and 3 others

CompletedFR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaThis phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma.NCT00077194·Washington D.C., District of Columbia and 3 others

UnknownPixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First RelapseRATIONALE: Drugs used in chemotherapy, such as pixantrone, cytarabine, methylprednisolone, and cisplatin, work in different ways to stop cancer cells from dividing so they stop…NCT00069966·Tucson, Arizona and 28 others

RecruitingBergamo Lymphoid Cancer RegistryThis registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancerNCT03131531·Bergamo

CompletedPhase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell MalignanciesThis is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.NCT00275431·Birmingham, Alabama and 10 others

UnknownTreatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood TransplantationThe purpose of this study is to evaluate the incidence of neutrophil engraftment after transplantation of one or two cord blood units meeting a predetermined total minimum cell…NCT00328237·Denver, Colorado

UnknownR2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHLIn this study，lenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma.NCT04152577·Jin'an, Shandong

CompletedRadioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin LymphomaThe study evaluates the additional use of radioimmunotherapy with a 90-Yttrium labeled monoclonal antibody targeting lymphoma cells in two dose reduced conditioning regimens for…NCT00302757·Berlin and 10 others

PreviousPage 181 of 330Next